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RadiotherapyhasbeenthemainstayofthetreatmentofstageIIInon-smallcelllungcancer(NSCLC)patients.Intheearlynineties,
combined treatment with chemotherapy was introduced. In 1995, a meta-analysis showed improved treatment outcome of the
sequential use of radiochemotherapy (RCT) compared to radiotherapy alone, provided cisplatin was part of the chemotherapy
course. Concurrent RCT compared to radiotherapy only yielded the same improvements of 4% in the 2-year and 2% in the 5-year
overall survival rates. Just recently, two meta-analyses demonstrated that concurrent RCT is deﬁnitely superior to sequential RCT
in terms of local control and 2-, 3-, and 5-year survival. However, several unanswered questions remain concerning the optimal
chemotherapy regimen and radiotherapy doses and techniques in terms of treatment outcome and toxicity proﬁle. Arguments
supporting a daily low-dose cisplatin scheme are presented because of comparable radiosensitizing characteristics and favourable
side eﬀects. Increasing radiotherapy doses applied according to up-to-date techniques and combinations with new biologicals
might lead to further treatment improvements.
1.Introduction
Until the nineties radiotherapy alone was the standard
treatment for stages IIIA and IIIB non-small cell lung cancer
(NSCLC). With the standard dose of 60 Gy in 30 fractions,
results in terms of 1-, 2-, and 5-year survival rates were poor
[1]. For NSCLC a dose-eﬀect relationship exists: the higher
the radiation dose, the greater the probability of tumour
control [2] .K o n ge ta l .r e p o r t e di m p r o v e dl o c a lc o n t r o l
and survival for patients irradiated with doses above 74Gy
in the dose escalation trial of the University of Michigan.
Strategiestoimprovethetreatmentresultsincludeincreasing
doses of radiotherapy and decreasing overall treatment time
[3]. A diﬀerent option is to combine radiotherapy with
chemotherapy. The ﬁrst report on improved 1- and 2-year
survival after adding chemotherapy to the irradiation was
published by Dillman et al. in 1990 [4].
2. SequentialRadiochemotherapy
The strategy of radiotherapy only changed essentially after
the publication of the meta-analysis by the Non-small Cell
Lung Cancer Collaborative Group in 1995 [5].
Radiotherapy preceded by (usually) two courses of
chemotherapy yielded an improvement of the 2-year overall
survival rate from 21% to 25%. The 5-year survival increased
from 6% to 8% provided that the chemotherapy regi-
men included cis-diamminedichloroplatinum II (cisplatin).
Without cisplatin no improvements in treatment outcome
were achieved.2 Chemotherapy Research and Practice
The eﬀect was explained by a reduction of distant metas-
tases. Until now this eﬀect of a lower distant metastasis rate
wasobservedinonestudyonly[6].Inthisstudy,LeChevalier
et al. compared radiotherapy alone to chemotherapy and
radiotherapy. However, patients with adenocarcinoma were
excluded. Since an important proportion of the NSCLC
patientswerenotincluded,theresultsmightnotberepresen-
tative. The 3-year survival rate was 12% for the combination
arm versus 4% for the radiotherapy arm (P<. 02). To our
knowledge, these results have never been conﬁrmed.
Until recently sequential cisplatin-containing radio-
chemotherapy has been the standard treatment for inopera-
blestageIIIAandBdisease.Variouschemotherapyschedules
have been applied, but the treatment outcome did not diﬀer
signiﬁcantly.
3. ConcurrentRadiochemotherapy
Ad i ﬀerent approach of combining chemotherapy and radio-
therapy was studied in Europe. After phase I and phase II
studies,theEORTCstarteda 3-armphaseIIItrialcomparing
split-course radiotherapy of 55Gy using the same radiother-
apy scheme, concurrently combined with 30mg/m2 cisplatin
once a week or 6mg/m2 daily in 1984 [7–9].
Theresultswerepublishedin1992[10].Themostimpor-
tant conclusions were as follows: weekly cisplatin adminis-
tration did not yield a statistically signiﬁcant improvement;
6mg/m 2 cisplatin daily added to radiotherapy improved
survival; this gain was related to improved local progression-
free survival. There was no eﬀect on the distant metastasis
rate, and late toxicity was not increased. These data demon-
strated that cisplatin improved the radiotherapy eﬀect by
radiosensitization. The most frequently reported acute side
eﬀects were nausea and vomiting. In 1992, Trovo et al. also
publishedtheirrandomisedphaseIIIstudy[11].Threeweeks
of radiotherapy, to a dose 45Gy, were compared to the same
radiotherapy dose with the addition of 6mg/m2 cisplatin
daily. No positive eﬀect on survival was found, however,
maybe due to the low radiation dose prescribed.
After the introduction of the newly developed antiemet-
ics, the 5-HT3 antagonists, several other groups reported
their results with concurrent radiochemotherapy in NSCLC.
Repeatedly two full-dose chemotherapy courses in a variety
of cisplatin, doublets or triplets were combined with radio-
therapy.
All phase III trials were included in a meta-analysis
by Aup´ erin et al, indicating a 4% survival gain at 2 years
and 2% at 5 years, for concurrent chemoradiation versus
radiotherapy alone, a comparable improvement as observed
with the sequential combination [12]. A Cochrane meta-
analysis conﬁrmed these conclusions [13]. The concomi-
tantly applied chemotherapy is considered to have radiosen-
sitizing capacities.
In the meantime EORTC study 08844 was followed by
phase I-II studies in which the radiotherapy was intensiﬁed
to reach an accelerated fractionation scheme (66Gy in 24
fractions) in a reduced overall treatment time (32 days)
[14, 15]. This radiobiologically equivalent dose of at least
78.5Gy/2Gy(BEDα/β = 2) with daily low-dose cisplatin
beforeeachfractionduring theentire coursewasfeasibleand
safe [16].
4.SequentialversusConcurrent
Radiochemotherapy
Several groups addressed the question of which type of
radiochemotherapy to prefer: the sequential or the concur-
rent combination. In several trials improved 1- and 2-year
overall survival rates in favour of the concurrent arm were
reported [17–23].
Most of these trials were included in a new meta-
analysis based on individual patient data by Aup´ erin et al,
who concluded that concurrent radiochemotherapy yielded
superior results compared to the sequential combinations: 2-
, 3-, and 5-year survival rates of 35.6%, 23.8%, and 15.1%
versus 30.3%, 18.1%, and 10.6%, respectively (P = .004)
[24]. This improved survival was accomplished because of
an improved locoregional control. There were no signiﬁcant
diﬀerences between the regimens: single or double high-dose
chemotherapy or daily low-dose cisplatin. No diﬀerences
in distant metastasis rate were observed between the two
approaches. Within a few months a meta-analysis was pub-
lished by O’Rourke et al. reporting a 10% absolute survival
beneﬁt at two years [25]. The most important acute but
manageable side eﬀe c tw a se s o p h a g i t i sg r a d e3t o4i n1 8 %
of the patients treated with concurrent radiochemotherapy
versus 4% in the patients treated with sequential RCT.
The conclusion was ﬁnalized: concurrent radio-
chemotherapy became the new standard treatment for
locally advanced nonmetastasized stages of NSCLC. It
should be realized that the trial data were collected in a
period before routine staging with FDG-PET and MRI of
the brain. In the future improved selection of the patients
will contribute to the treatment results.
5. UnansweredQuestions
New questions arise, however: what is the optimal com-
bination of chemotherapy used concurrently with high-
dose radiotherapy? To answer this question we took a
closer look at the toxicities of the trials included in the
meta-analysis of Aup´ erin et al. [24]. Arbitrarily we selected
those studies that included at least 50 patients in the
concurrent arm to assemble more reliable data. In the
Furuse trial 80mg/m2 cisplatin was given on days 1 and
29, combined with vindesine 3mg/m2 on days 1, 8, 29, and
36 and mitomycin 8mg/m2 on days 1 and 29 with 56Gy,
2Gy/fraction, split-course radiotherapy [20]. In the French
trial cisplatin was prescribed during weeks 1 and 5 using a
daily dose of 20mg/m2 together with 50mg/m2 etoposide.
Theradiotherapydosewas66Gyin33fractionsin6.5weeks,
followed by two consolidation cycles consisting of cisplatin
and vinorelbine [19] .T h eE O R T Ct r i a lp r e s c r i b e d6m g / m 2
cisplatin daily combined with 2.75Gy radiotherapy, total
dose 66Gy/24 fractions, 5 fractions a week [23].
The study of Zatloukal et al., missing in the meta-
analysis, prescribed 80mg/m2 cisplatin on day 1 and vinorel-
bine 25mg/m2 on days 1, 8, and 15, repeated every 28Chemotherapy Research and Practice 3
Table 1: Survival data and toxicities of concurrent treatment regimens with >50 patients included.
Author of publication Zatloukal et al. [22]F o u r n e l e t a l . [ 19] Furuse et al. [20]B e l d e r b o s e t a l . [ 23]
Number of patients 102 205 314 158
Survival data (%)
Overall survival 2 years 34.2 26.5 34.6 34
Overall survival 3 years 18.6 18.6 22.3 29.2
Acute toxicity (%)
Neutropenia grade 3 + 4 65 77 100 2
Thrombocytopenia 6 16 53 0
Anaemia 12 20 10 0
Esophagitis 18 32 3 17
Nausea/vomiting 39 24 22 6
days. The radiotherapy, 60Gy/30 fractions during 6 weeks,
was started on day 4 resulting in a weekend rest between
the chemotherapy administration and start of radiotherapy
[22]. The treatment results in terms of 2- and 3-year overall
survival are plotted in Table 1 and seem comparable to the
dailylow-dosecisplatinoutcome.FortheRTOGstudynofull
paper has been published, and important data on toxicity are
lacking [18].
The treatment-related toxicities are listed in Table 1 as
well. In general high-dose cisplatin was accompanied by
more frequent haematological toxicity. Esophagitis was 3%
in the split-course radiotherapy scheme and more or less
equal (18%) for the other varieties with exception for the
study by Fournel et al. Nausea and vomiting was much lower
for the daily low-dose cisplatin combination. Other toxicities
such as neuropathy, renal toxicity, and pneumonitis were
reported in diﬀerent ways and were generally infrequent if
presented. Fournel reported a striking toxic death rate of
11%, maybe also related to the combination with consol-
idation chemotherapy treatment. Many patients were not
capable to receive the two additional courses after ﬁnishing
the concurrent radiochemotherapy.
The mild toxicity proﬁle of daily 6mg/m2 cisplatin and
competitive clinical outcome with accelerated radiotherapy
compared to full-dose concurrent RCT supports the use of
this scheme, although randomized prospective clinical trials
will ﬁnally yield the proof. To our knowledge until now no
such studies have been performed.
In the study of Belderbos et al. the radiation dose was the
highest compared to the schemes used in the other reports
[23].
Trials studying the role of induction or consolidation
chemotherapy show disappointing results [26, 27].
6. Other Arguments inFavourof
DailyLow-DoseCisplatin
Since the incidence of NSCLC is high among elderly patients
(at least 40% of the patients are older than 70 years in The
Netherlands) and many of them have a smoking history, the
majority has severe comorbidities. Epidemiological studies
show that, with increasing age, the percentage of people
treated with chemotherapy decreases. However, age is not
an independent prognostic factor in stage III and IV
NSCLC [28–30]. Elderly patients with marginal renal func-
tion (creatinine clearance <70mL/min) or marginal cardiac
function (hyperhydration contra-indicated) are eligible for
administration of daily low-dose cisplatin, while adminis-
tration of full-dose chemotherapy is often contraindicated.
Combination of concurrent daily cisplatin with radiation
appears to be a good alternative, especially in these elderly,
frail patients [31, 32].
For patients with head and neck tumours, hearing loss
due to cisplatin administration was studied and reported
low in case of daily low-dose cisplatin compared to high-
dose courses [33]. Preclinical studies on RCT support the
use of daily administration for optimal radiosensitizing
eﬀects [34]. However, when logistics make this daily admin-
istration too complicated, a weekly cisplatin dose can be
considered (40mg/m2) to conform with the guidelines for
radiochemotherapy in patients with cervical cancer [35].
Alternative platinum compounds such as carboplatin
havenotyieldedthesamepositiveresultsascisplatin[36,37].
To our opinion the favourable toxicity proﬁle makes
the daily low-dose cisplatin with high-dose accelerated
radiotherapy combination suitable for addition of new
antitumour agents. Many new biologicals have entered the
therapeutic domain, several were combined with concurrent
RCT regimens. Some combinations appear to be too toxic
like the vascular epithelial growth factor antibody beva-
cizumab [38] or ineﬀective as the tyrosine kinase inhibitor
(TKI) geﬁtinib [39]. The feasibility of adding the epidermal
growth factor receptor inhibitor cetuximab has been recently
reported for NSCLC patients [40]. Results of a running
randomized phase II trial comparing daily cisplatin with
or without cetuximab need to be awaited. Studies on the
antifolate pemetrexed are under way [41]. Until now no
deﬁnite data can be reported.
Other topics for future research are RCT with more
sophisticated radiotherapy techniques allowing possibly
higher tumour doses and/or lower toxicities in surrounding
healthy tissues. For patients with larger tumor volumes,
the possibilities to increase the radiation dose were limited
by normal tissue constraints (esophagus and spinal cord).4 Chemotherapy Research and Practice
Intensity-modulated radiotherapy (IMRT) has the potential
beneﬁt to further increase the dose that can be safely
prescribed in lung cancer patients due to a better conformity
index and a steeper dose falloﬀ [42–44]. This technique has
been widely introduced recently.
7. Conclusions
In conclusion after two decades of mainly sequentially com-
bined treatment, concurrent radiochemotherapy is nowa-
days the standard treatment. Since the daily low-dose
cisplatin can be safely combined with high-dose accelerated
radiotherapy, this treatment option is still very appealing. In
general oncologists should oﬀer the least harmful treatment
to their patients in case several treatment options are
available with equal eﬃcacy.
This approach, delivered in a short overall treatment
time, is suitable for the elderly and for patients with comor-
bidities as well. It also oﬀers the opportunity to combine this
concomitant radiochemotherapy with new agents.
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